Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 0.68 |
| ▸ | MASP2 | O00187 | 1/20 | 0.68 |
| ▸ | CMA1 | P23946 | 3/20 | 0.60 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211679 | 1.00 | CTSG (0.68) | CTSGMASP2CMA1ACP3DRD2 | |
| SCHEMBL1614368 | 0.91 | CTSG (0.63) | CTSGMASP2CMA1ACP3DRD4 | |
| SCHEMBL1614713 | 0.90 | CTSG (0.62) | CTSGMASP2CMA1ACP3DRD2 | |
| SCHEMBL1614758 | 0.90 | CTSG (0.56) | CTSGMASP2CMA1ACP3DRD2 | |
| SCHEMBL4186282 | 0.86 | CTSG (0.55) | CTSGMASP2CMA1ACP3EPHX1 | |
| SCHEMBL4200589 | 0.85 | NPC1 (0.56) | CTSGMASP2CMA1ACP3EPHX1 | |
| SCHEMBL4452557 | 0.85 | CTSG (0.59) | CTSGMASP2CMA1ACP3DRD2 | |
| SCHEMBL4189774 | 0.81 | CTSG (0.52) | CTSGMASP2CMA1ACP3DRD2 | |
| SCHEMBL1613660 | 0.81 | CTSG (1.00) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL31211813 | 0.81 | CTSG (1.00) | CTSGMASP2CMA1ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304430-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-20110086819-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | GRECO MICHAEL N | 2011-04-14 | — | — | US | claimed |
| EP-1438316-B1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARM INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | claimed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20230364037-A1 | CANCER THERAPEUTIC | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2023-11-16 | — | — | US | disclosed |
| US-20200197335-A1 | CANCER THERAPEUTIC | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2020-06-25 | — | — | US | disclosed |
| US-20200041521-A1 | CANCER DIAGNOSIS AND THERAPY | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2020-02-06 | — | — | US | disclosed |
| US-10281472-B2 | Cancer diagnosis and therapy | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2019-05-07 | — | — | US | disclosed |
| US-20190048416-A1 | TREATMENT OF FIBROTIC CONDITIONS | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2019-02-14 | — | — | US | disclosed |
| US-20170360829-A1 | TREATMENT OF VASCULAR ANOMALIES | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-12-21 | — | — | US | disclosed |
| US-20170234884-A1 | CANCER DIAGNOSIS AND THERAPY | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
| US-20110086819-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.